Dr Tim Boyle joined ARCS Australia as CEO in November 2023, previously serving in senior leadership and executive roles at ANSTO. A recognized leader in research translation and IP commercialisation, he has over two decades of experience in technology licensing and developing science based ventures. Previously Tim also served as Executive Chair of ATTP, and is a life member and former non-executive director of Knowledge Commercialisation Australasia. Tim also holds appointments as an Adjunct Professor at Swinburne University of Technology, and Global Expert Faculty at Singularity University.

With over 25 years of experience, Nicholette has worked in pharmaceuticals, medical devices, and diagnostics, with a commitment to equitable patient access to innovative treatments. She has worked with precision medicine and health tech startups, biotech and medtech scale-ups, and worked in major pharmaceutical companies including Eli Lilly, Amgen, MSD, and Bayer. Her expertise spans clinical development (Phase 1-3), Health Technology Assessment (HTA) new product planning (NPP), market access, and reimbursement (MSAC & PBAC), and she has successfully led commercial strategy, product development and implementation projects across oncology, rare diseases, infectious diseases, chronic disease, reproductive technologies, and genetics. Her approach is pragmatic and holistic, includes broad and diverse stakeholder engagement, and especially the inclusion of patients and their care givers to guide care. Nicholette is the current Board Chair of Genetic Alliance Australia and is passionate about enabling patient access to new technologies and precision medicine through multi-disciplinary collaboration.

Anne-Maree is passionate about the potential of innovative technologies to improve health outcomes. An engineer by trade, she also has a masters in public policy, and combines a thorough knowledge of product development with a strong understanding of the broader health and innovation policy landscape. She started her career at the medical device innovator Cochlear, has been the Operations Manager at health IT startup Humanetix, and also spent several years as Policy Manager at pharmaceutical company MSD. She is currently Head of Strategic Policy Implementation at Medicines Australia.

Tiffany Boughtwood is the Managing Director of Australian Genomics, an Australian Government initiative supporting genomic research and its translation into clinical practice through broad engagement and a collaborative national approach. Tiffany has 25 years’ experience in molecular biology and management: leading academic and diagnostic genomic programs; collaborating internationally in genetic and genomic research; and consulting in health genomic implementation. She served on the World Economic Forum Global Future Council for Biotechnology and the WHO Collective Global Network for Rare Disease, and advised the initiation of the UAE Genomic Program. Tiffany is a member of the WHO Technical Advisory Group on Genomics and is a Director of the Childhood Dementia Initiative.

Graduated from UWA with a Master of Science in Clinical Biochemist and worked in pathology labs for 15 years. Moved to sales, marketing and executive management roles, mostly in large IVD technology companies. Has lived and worked in the USA, China and almost all Asian and sub-continental countries. Dean has an extensive knowledge of the pathology testing and technology sector. He supported the early days of Australia’s Bowel Cancer Screening program roll out. Currently heading up Pathology Technology Australia - the peak body representing companies that develop, manufacture and supply the technology and consumables so vital to testing in human health.

20+ years of experience across roles in Regulatory, Quality, Project Management, Customer Solutions & Market Access in Regulatory Agencies and MedTech, Pharmaceutical and Cell & Gene organisations. At ARCS 2024, I'm representing InGeNA (Industry Genomics Network Alliance) at the Cell & Gene panel discussion on 14th June from 9:30 to 10.30am

Dr Marguerite Evans-Galea AM is an influential leader in Australia’s health ecosystem and has received multiple awards for her research and leadership. She is Director of Australia’s Cell and Gene Catalyst, a national joint venture of the industry peak bodies, AusBiotech and Medicines Australia, that aims to accelerate Australia’s cell and gene industry across the value chain and enable equitable access to these advanced therapies. During her 18-year research career, Dr Evans-Galea led international pre-clinical research programs in cell and gene therapy for inherited diseases at St. Jude Children’s Research Hospital in the United States and at the Murdoch Children’s Research Institute in Australia. She has received multiple awards for her research and leadership. Dr Evans-Galea is also an experienced consultant, editor, author and peer reviewer. Dr Evans-Galea has developed, established and led high-impact national STEM workforce initiatives with the Australian Learned Academies, including the IMNIS industry engagement initiative and the Australian Government’s $41.2 million Elevate: Boosting Women in STEM program with the Australian Academy of Technological Sciences (ATSE). Playing a pivotal role in boosting diversity and inclusion in the Australian STEM sector, Dr Evans-Galea cofounded Women in STEMM Australia and served on the Ministerial Council for Women’s Equality in Victoria and the SAGE Expert Advisory Group. Dr Evans-Galea has an Australian Leadership Award and the Vice-Chancellor's Alumni Excellence Award from The University of Queensland. She has also been inducted into the Victorian Honour Roll of Women and is a Member of the Order of Australia.